Nomir Medical Technologies, a developer of optical energy technologies for medical applications, announced today that the U.S. Patent and Trademark Office has granted a central patent to Nomir that further protects its core Noveon technology. Noveon is a light-based system that photobiologically targets the elimination of bacterial and fungal infections using a near-infrared, photoinactivation effect.
This latest patent (No. 7,470,124) protects the photoinactivation and eradication of microorganisms as a result of application of Noveon energies through a suite of flexible root canal dispersion tips, according to Nomir.
"The granting of this patent further differentiates Nomir as a photobiology company, as the Noveon's unique action spectrum is proven safe, and is well beyond the mutagenic ultraviolet or photo-thermal ablative wavelengths and power ranges traditionally used for anti-infective indications," Eric Bornstein, Nomir's chief scientific officer, stated in a press release. "We expect this technology will aid the dental community in root canal disinfection procedures, ultimately making root canal procedure outcomes more predictable and successful."
To date, Nomir has conducted six different institutional review board (IRB) human studies with this technology and has demonstrated "promising results" in the areas of onychomycosis, methicillin-resistant Staphylococcus aureus (MRSA) infection, and periodontal disease, according to the company.
